Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (290)	3/23/2002 10:26:50 AM
From: Mike McFarland	Read Replies (2) \| Respond to of 1336

Reminder to self/CEGE Mon March 25 11:20 a.m. EST (thank you Wilder) Maybe we will hear something more about what Rigel has done for cege in the way of angiogenesis targets. Press Release SOURCE: Cell Genesys Cell Genesys Invites You to Join Its Company Presentation at the New York Society of Security Analysts 6th Annual Health Care Conference on the Web NEW YORK, March 22 /PRNewswire/ -- In conjunction with Cell Genesys' company presentation at the New York Society of Security Analysts (NYSSA) 6th Annual Health Care Conference, you are invited to listen to the presentation that will be broadcast live over the Internet on Monday, March 25, 2002, at 11:20 a.m. EST with Matthew J. Pfeffer, vice president and chief financial officer of Cell Genesys (Nasdaq: CEGE - news). Mr. Pfeffer is expected to provide an update on plans for presentations describing certain of the company's clinical programs at the May 2002 meeting of the American Society of Clinical Oncology (ASCO). What: Cell Genesys Company Update NYSSA 6th Annual Health Care Conference When: Monday, March 25, 2002, at 11:20 a.m. EST Where: www.cellgenesys.com How: Live over the Internet -- Simply log on to the web at the address above Contact: Jennifer Cook Williams 650-425-4542 Cell Genesys is focused on the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and in vivo cancer gene therapies. Clinical trials of GVAX® vaccines are under way in lung cancer, prostate cancer, pancreatic cancer, leukemia and myeloma. Clinical trials of oncolytic virus therapies include CG7060 and CG7870 in prostate cancer. Preclinical stage programs include oncolytic virus therapies and gene therapies for multiple types of cancer. Cell Genesys' majority-owned subsidiary, Ceregene, is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold approximately nine million shares of common stock in its former subsidiary, Abgenix, an antibody products company. Cell Genesys is headquartered in Foster City, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company's website at www.cellgenesys.com. If you are unable to listen to the live webcast, the presentation will be archived on www.cellgenesys.com and will be available within one hour following the presentation for two weeks. SOURCE: Cell Genesys

To: Mike McFarland who wrote (290)	3/23/2002 5:56:49 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

Skimming through recent posts, I see that I tend to mention buys and not very often sells. fwiw, I don't right now own any eln, mlnm, gern, lsbc, or orch. I do have some vgnx, the tgen and rigl, the sampler of cege, a splash of snap. We have already done some googling around regarding genxy today. The only other thing I can think of us vlts...which of course is on a tear recently after I dropped it. Typical. Those other things I listed have popped in and out of my account from time to time in the past couple months. The trades have not done much for me. I don't want to create the impression that I've dipped into my cash to do any really significant buying. I always seem to stay around 75% cash-- plus or minus ten percent these days. My CD is coming due. I hate to say it, but it is likely I'll just roll it over. I see increasing interest in things like gold. I have no use for that junk.